Liquid Biopsy-Based Multicancer Early Detection Test May Detect Early-Stage Disease and Low DNA-Shedding Cancers; Multicancer Early Detection Platform Was Developed Based on Methylation of Cell-Free DNA; Study Presented at AACR 2023

A liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers, according to data from a retrospective study presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19 in Orlando, Florida. “Detection of cancer in early stages through screening programs has been demonstrated to save lives. However, only a few cancer types have screenings available today, and the majority of cancer deaths are from cancers for which there are no screening methods,” said presenter Ben Ho Park, MD, PhD, Benjamin F. Byrd Jr. Professor of Oncology, Director of the Vanderbilt-Ingram Cancer Center, and Professor of Medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center.

Login Or Register To Read Full Story